Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial

(2014) Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial. European Neuropsychopharmacology.

Full text not available from this repository.

Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....

Abstract

Considering the role of neurohypophyseal peptides in normal development and function of higher cortical processes along with their proven abnormalities in schizophrenic patients, these pathways have recently attracted greater attention as treatment targets for schizophrenia. Desmopressin (DDAVP) is a synthetic analog of vasopressin. This study aimed to evaluate the efficacy and safety of DDAVP nasal spray as an adjunct to risperidone in improving negative symptoms of schizophrenia. In this randomized double-blind placebo-controlled clinical trial, forty patients aged 18-50 years with a DSM IV-TR diagnosis of chronic schizophrenia and a minimum score of 60 on positive and negative syndrome scale (PANSS) were equally randomized to receive DDAVP nasal spray (20. mcg/day) or placebo in addition to risperidone for 8 weeks. Patients were partially stabilized and treated with a stable dose of risperidone (5 or 6. mg/day) for at least four weeks prior to entry. Participants were rated by PANSS every two weeks and decrease in the PANSS negative subscale score was considered as our primary outcome. By the study endpoint, DDAVP-treated patients showed significantly greater improvement in the negative symptoms (P=0.001) as well as the PANSS total and general psychopathology subscale scores (P=0.005 and P=0.003; respectively) compared to the placebo group. Treatment group was the strongest predictor of changes in negative symptoms (β=-0.48, t=-3.67, P=001). No serious adverse event or fluid/electrolyte imbalance was reported in this trial. In conclusion, DDAVP nasal spray showed to be an effective and safe medication for improving negative symptoms in patients with chronic schizophrenia. © 2014 Elsevier B.V. and ECNP.

Item Type: Article
Keywords: desmopressin; nose spray; placebo; risperidone; argipressin1 deamino; neuroleptic agent; risperidone, add on therapy; adult; article; clinical article; clinical evaluation; controlled study; coughing; double blind procedure; drowsiness; drug efficacy; drug safety; DSM-IV-TR; electrolyte disturbance; female; fever; headache; human; increased appetite; male; multicenter study; nausea; negative syndrome; Positive and Negative Syndrome Scale; priority journal; pruritus; randomized controlled trial; schizophrenia; treatment outcome; xerostomia; adolescent; Diagnostic and Statistical Manual of Mental Disorders; drug combination; intranasal drug administration; middle aged; psychological rating scale; psychology; schizophrenia; young adult, Administration, Intranasal; Adolescent; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult
Page Range: pp. 846-855
Journal or Publication Title: European Neuropsychopharmacology
Volume: 24
Number: 6
Publisher: Elsevier
Identification Number: 10.1016/j.euroneuro.2014.02.001
ISSN: 0924977X
Depositing User: مهندس جمال محمودپور
URI: http://eprints.muk.ac.ir/id/eprint/1069

Actions (login required)

View Item View Item